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OBJECTIVE—The hormone ﬁbroblast growth factor 21
(FGF21) exerts diverse, beneﬁcial effects on energy balance and
insulin sensitivity when administered systemically to rodents
with diet-induced obesity (DIO). The current studies investigate
whether central FGF21 treatment recapitulates these effects.
RESEARCH DESIGN AND METHODS—After preliminary
dose-ﬁnding studies, either saline vehicle or recombinant human
FGF21 (0.4 g/day) was infused continuously for 2 weeks into
the lateral cerebral ventricle of male Wistar rats rendered obese
by high-fat feeding. Study end points included measures of
energy balance (body weight, body composition, food intake,
energy expenditure, and circulating and hepatic lipids) and
glucose metabolism (insulin tolerance test, euglycemic-hyperin-
sulinemic clamp, and hepatic expression of genes involved in
glucose metabolism).
RESULTS—Compared with vehicle, continuous intracerebro-
ventricular infusion of FGF21 increased both food intake and
energy expenditure in rats with DIO, such that neither body
weight nor body composition was altered. Despite unchanged
body fat content, rats treated with intracerebroventricular
FGF21 displayed a robust increase of insulin sensitivity due to
increased insulin-induced suppression of both hepatic glucose
production and gluconeogenic gene expression, with no change
of glucose utilization.
CONCLUSIONS—FGF21 action in the brain increases hepatic
insulin sensitivity and metabolic rate in rats with DIO. These
ﬁndings identify the central nervous system as a potentially
important target for the beneﬁcial effects of FGF21 in the
treatment of diabetes and obesity. Diabetes 59:1817–1824,
2010
F
ibroblast growth factor (FGF) 21 is a FGF family
member produced by liver and other tissues that
plays an important role in the control of energy
balance and glucose metabolism (1). In addition,
when administered at pharmacologic doses, FGF21 in-
duces wide-ranging beneﬁcial effects in animal models of
obesity and diabetes (2). Speciﬁcally, in obese rodents,
pharmacologic FGF21 treatment reduces body fat content
and improves glucose tolerance, insulin sensitivity, and
lipid parameters (both circulating and hepatic) (3–5).
Consequently, FGF21 has emerged as a novel target for the
treatment of obesity and associated metabolic dysfunction
(2). FGF21-mediated weight loss appears to involve in-
creased fat oxidation and metabolic rate with no change of
food intake (3). Whether the insulin-sensitizing effects of
FGF21 are dependent on reduced body fat or involve
other, independent mechanisms has not been established.
Interestingly, these insulin-sensitizing effects are attribut-
able largely to enhanced insulin action in the liver (6), and
yet recent evidence suggests that FGF21 regulates hepatic
substrate metabolism via a mechanism that cannot be
explained by a direct effect on hepatocytes (6).
The diverse and indirect nature of these pharmacologic
effects raises the possibility that at least some actions of
FGF21 might be mediated centrally. This hypothesis is
consistent with growing evidence implicating the hypo-
thalamus and other regions of the central nervous system
(CNS) in adaptive adjustments of insulin sensitivity trig-
gered by changing levels of key hormones and nutrients in
the circulation (7). To determine whether metabolic ef-
fects observed during systemic FGF21 treatment might
involve a central site of action, we infused FGF21 into the
brain of diet-induced obesity (DIO) rats at a low dose that
does not leak into the circulation in detectable amounts.
RESEARCH DESIGN AND METHODS
Male Wistar rats (250–275 g; Harlan, Indianapolis, IN) were individually
housed and provided with ad libitum access to water and a high-fat diet (HFD)
(60 kcal % from fat, D12492; Research Diets, New Brunswick, NJ) for 8 weeks
before study. Lean LA/N rats (Vassar College, Poughkeepsie, NY) were
maintained on standard rat chow (Purina, St. Louis, MO). All procedures
were performed in accordance with National Institutes of Health Guide-
lines for the Care and Use of Animals and were approved by the
university’s Animal Care Committee.
Central FGF21 infusion. Under isoﬂurane anesthesia, each rat received
a cannula (Alzet, infusion kit II; DURECT, Cupertino, CA) implanted ster-
eotaxically into the right lateral ventricle (0.8 mm posterior to bregma, 1.5 mm
lateral to the midline, and 3.5 mm below the surface of the skull), ﬁxed onto
the skull with dental cement and connected via polyethylene tubing to a
subcutaneously implanted 14-day osmotic minipump (Alzet, model 2002).
Minipumps were ﬁlled with either recombinant human (h) FGF21 (Prospec,
Rehovot, Israel) dissolved in 0.1% BSA containing saline or vehicle only (0.1%
BSA saline solution).
Body composition, locomotor activity, and indirect calorimetry. Deter-
minations of total body lean and fat mass and liver triglyceride content were
made using quantitative magnetic resonance spectroscopy (Echo Medical
Systems, Houston, TX). Locomotor activity was assessed by the infrared beam
breaks using an Opto-Varimetrix-3 sensor system (Columbus Instruments,
Columbus, OH). Indirect calorimetry was performed with a computer-con-
trolled calorimetry system (Oxymax; Columbus Instruments). VO2 and VCO2
were normalized to lean body mass. Energy expenditure (EE) was calculated
based on EE  3.815  VO2  1.232  VCO2 (8).
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dures (intracerebroventricular cannulation and implantation of arterial and
venous catheters) at least 6 days before study, as previously described (9).
After a 16-h fast, rats were placed into an animal enclosure that allowed
simultaneous sampling of arterial blood while infusing into the jugular vein.
The clamp protocol (9) included a 2-h basal period during which only
[3-
3H]glucose tracer was infused. Two hours after the basal period, a primed
continuous infusion of regular human insulin (60 mU/kg bolus followed by 1.8
mU  kg
1  min
1 Humulin R (Eli Lilly, Indianapolis, IN) was administered at
t  0 min, and a 50% dextrose solution was infused to maintain euglycemia.
Serial blood samples were obtained throughout the basal and clamp periods
for determination of plasma glucose and insulin levels and for calculation of
glucose turnover rates as described (9).
Insulin and glucose tolerance tests. After 10 days of intracerebroventric-
ular infusion, an insulin tolerance test (ITT) was performed after a 4-h fast in
the midlight cycle by an injection of insulin (0.75 units/kg i.p. for DIO rats and
0.5 units/kg i.p. for lean rats; Humulin R), with glucose levels determined at
indicated time points on blood samples taken from tail vein blood using a
hand-held glucometer (Accu-Chek; Roche, Basel, Switzerland). Glucose toler-
ance tests were also conducted after an overnight fast. After an intraperitoneal
injection of 30% D-glucose (2.5 g/kg) (Abbott Laboratories, North Chicago, IL),
glucose levels were measured in blood obtained from the tail vein at the
indicated times points.
Serum and liver analysis. Plasma insulin and hFGF21 levels were deter-
mined by ELISA (Crystal Chem, Downers Grove, IL, and BioVendor, Modrice,
Czech Republic, respectively). Plasma free fatty acids (FFAs) and triglycer-
ides were measured using colorimetric assay (Wako Chemicals, Richmond,
VA). Analysis of liver glycogen content was performed using an calorimetric
assay according to the manufacturer’s instructions (BioVision, Mountain
View, CA).
RT-PCR. RNA extraction, reverse transcription and real-time PCR for
ampliﬁcation of Pepck, G6Pase, ACC2, Foxa2, PGC1, PPAR, SCD1, and
SREBP-1c was performed as previously described (9).
Statistical analysis. All results are expressed as means  SEM. A one-way
ANOVA with a least signiﬁcant difference post hoc test was used to compare
mean values between multiple groups and a two-sample, unpaired Student t
test was used for two-group comparisons. P  0.05 was considered signiﬁcant.
RESULTS
Effect of intracerebroventricular hFGF21 infusion on
energy balance and body composition in DIO rats. Our
ﬁrst goal was to identify a dose of hFGF21 that does not
enter the plasma in detectable amounts when adminis-
tered centrally. To conﬁrm our ability to detect hFGF21
immunoreactivity in the circulation, plasma from mice
receiving a continuous subcutaneous hFGF21 (0.2 mg/kg/
day) infusion was analyzed. As expected, hFGF21 immu-
noreactivity was readily detected (14.6  0.2 g/ml) using
an hFGF21-speciﬁc ELISA on plasma taken from these
mice. We next administered either vehicle or one of three
doses of hFGF21 (4.0, 0.40, and 0.04 g/day; each well
below doses that induce metabolic effects during systemic
administration) (3,4) as a continuous infusion into an
indwelling cannula inserted into the lateral ventricle of
adult male Wistar rats. For 8 weeks before brain cannula-
tion, rats were rendered obese by consuming HFD, and
after 14 days of intracerebroventricular infusion, leakage
of hFGF21 from brain into plasma was assessed. Although
hFGF21 was clearly detected in the plasma of rats receiv-
ing continuous intracerebroventricular infusion of the
highest dose (4.0 g/day) of hFGF21 (0.91  0.86 g/ml),
neither of the lower doses (0.04 or 0.40 g/day) detectably
increased plasma levels (not shown). Therefore, hFGF21
does not detectably enter plasma during continuous intra-
cerebroventricular infusion of up to 0.4 g/day.
Continuous intracerebroventricular infusion of hFGF21
at doses of either 0.04 or 0.40 g/day was without effect on
body weight or body composition throughout a 14-day
period of observation (mean body weight  581.9 
10.4 g) compared with weight-matched, vehicle-treated
rats consuming an identical HFD (Fig. 1A and B). Given
this outcome, we were somewhat surprised to observe
that animals receiving intracerebroventricular hFGF21 at
0.40 g/day consumed 20–30% more food than vehicle-
treated controls from days 4–10 of infusion (Fig. 1C and
D). To explain these divergent ﬁndings, we hypothesized
that intracerebroventricular hFGF21 infusion also in-
creases energy expenditure, as occurs with systemic ad-
ministration (3), such that neutral energy balance is
maintained. To test this hypothesis, we used indirect
calorimetry to measure rates of VO2 and VCO2 in rats after
10 days of continuous intracerebroventricular infusion of
either vehicle or hFGF21 (0.40 g/day) while consuming
the same HFD. Both VO2 and energy expenditure tended to
be higher in the hFGF21-treated group compared with
controls throughout the observation period (Fig. 1E and
F), and this effect achieved statistical signiﬁcance during
the light cycle (when animals are relatively inactive), but
not during the dark cycle (P  0.05). This pattern of
increased energy expenditure in the light cycle suggests
but does not establish that resting metabolic rate was
increased by central hFGF21 infusion. By comparison,
respiratory quotient (a measure of fat vs. carbohydrate
oxidation) and ambulatory activity were not different
between groups (data not shown).
Effect of central hFGF21 infusion on insulin sensitiv-
ity in DIO rats. As a ﬁrst step to determine whether
hFGF21 action in the brain increases insulin sensitivity,
we performed an ITT after 5 days of continuous intrace-
rebroventricular infusion of either hFGF21 or saline in rats
fed a HFD. Insulin-induced glucose lowering was in-
creased by intracerebroventricular hFGF21 at the 0.40
g/day dose relative to vehicle (Fig. 2A), suggesting im-
proved insulin sensitivity, although differences of baseline
(4 h food-deprived) blood glucose and plasma insulin
levels were not detected (Fig. 2C and D). We also found no
differences in liver triglyceride content (Fig. 2E), and
although liver glycogen content tended to be higher in
intracerebroventricular hFGF21-infused rats (Fig. 2F), this
difference did not reach statistical signiﬁcance (P  0.06).
To further investigate the effect of centrally adminis-
tered hFGF21 on insulin sensitivity, we performed eu-
glycemic-hyperinsulinemic clamp studies in separate
groups of weight-matched, HFD-fed rats on day 7 of
continuous intracerebroventricular infusion of either
saline or hFGF21 (0.40 g/day). As in our previous studies,
intracerebroventricular infusion of hFGF21 had no effect
on body weight (despite increased cumulative food in-
take), nor did it alter fasting plasma insulin, triglyceride, or
FFA levels (Table 1). Although fasting glucose levels
tended to be lower in hFGF21-treated rats, this effect did
not achieve statistical signiﬁcance (P  0.08).
During the clamp procedure, arterial glucose and
plasma insulin concentrations were matched between
groups (by design) (Fig. 2H, Table 1), but the glucose
infusion rate (GIR) needed to maintain euglycemia was
increased by 70% in animals receiving intracerebroventric-
ular hFGF21 compared with vehicle (Fig. 2G, Table 1),
establishing that hFGF21 action in the brain increases
insulin sensitivity in obese, HFD-fed rats. This was accom-
panied by an effect of intracerebroventricular hFGF21 to
enhance the effect of insulin to lower the rate of glucose
appearance (measured as the difference in Ra between the
basal and clamped states) (Fig. 3A) relative to rats receiv-
ing intracerebroventricular vehicle, such that insulin-me-
diated suppression of hepatic glucose production was
increased by twofold (Fig. 3B). By comparison, the rate of
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tricular hFGF21 during either basal or clamp periods (Fig.
3C and D). Moreover, plasma hFGF21 immunoreactivity
was not detected in either group, conﬁrming that intrace-
rebroventricular-infused hFGF21 did not leak into the
periphery (Table 1). Samples taken after the completion of
the clamp revealed no difference in liver triglyceride
content between groups (18.3  1.2 vs. 17.2  1.4% for
hFGF21 vs. vehicle; NS), nor were there differences in liver
glycogen content (Table 1). Thus, hFGF21 action in the
CNS improves hepatic insulin sensitivity of rats with DIO
without altering either total body or hepatic fat content.
To gain further insight into the mechanism underlying
the insulin-sensitizing effects of intracerebroventricular
hFGF21, we measured expression of two key gluconeo-
genic genes, glucose-6-phosphatase (G6Pase) and phos-
phosphoenolpyruvate carboxykinase (Pepck), in liver
samples obtained both in the basal state (after a 4-h fast)
and after the completion of clamp (insulin-stimulated).
Among clamped animals, hepatic expression of both
G6Pase and Pepck mRNA was signiﬁcantly reduced (by 52
and 47%, respectively) in animals receiving intracerebro-
ventricular hFGF21 (Fig. 4A), whereas in the basal state,
Pepck mRNA levels were unchanged and expression of
G6Pase mRNA was slightly increased by intracerebroven-
tricular hFGF21 (Fig. 4B). Thus, intracerebroventricular
hFGF21 augments insulin-mediated inhibition of hepatic
G6Pase and Pepck expression, an effect that was absent (if
not reversed) in the absence of insulin stimulation.
Our observation of increased caloric intake despite no
change in total body or hepatic fat content in rats receiving
intracerebroventricular hFGF21 led us to ask whether
hepatic expression of genes involved in lipid metabolism is
altered by this treatment. In the insulin-stimulated state
(postclamp), hepatic mRNA expression of the lipolytic
gene forkhead box A2 (Foxa2) was increased (by 77%),
whereas mRNA expression levels of the lipogenic genes
sterol regulatory element-binding protein-1c (SREBP-1C)
and stearoyl-CoA desaturase-1 (SCD1) were reduced (by
50 and 55%, respectively) by intracerebroventricular
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FIG. 1. Effect of central hFGF21 infusion on energy homeostasis in DIO rats. Percent body weight change (A), body composition (B), daily food
intake (C), cumulative food intake (D), VO2 (E), and energy expenditure (F) in adult male rats with DIO (n  6 per group) receiving continuous
intracerebroventricular infusion of either hFGF21 (0.04 and 0.40 g/day) or vehicle. For clarity, VO2 and energy expenditure data in E and F are
presented as 3-h averages over three consecutive 12-h dark (D1–3) and two 12-h light (L1–2) cycles. *P < 0.05 vs. vehicle (Veh).
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the basal state (4-h fast), these effects were reversed such
that intracerebroventricular hFGF21 induced a slight but
signiﬁcant increase of hepatic SREBP-1C mRNA levels
and a doubling of acetyl-CoA carboxylase-2 (ACC2) mRNA
content (Fig. 4B), consistent with decreased lipid oxida-
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FIG. 2. Central infusion of hFGF21 improves insulin sensitivity in DIO rats. Percent basal blood glucose levels (A), inverse area under the curve
(B) during ITT, 4-h fasted blood glucose (C), plasma insulin levels (D), hepatic fat (E), and glycogen content (F) obtained from male Wistar rats
with DIO (n  6 per group) that received continuous intracerebroventricular infusion of either hFGF21 (0.40 g/day) or vehicle for 2 weeks.
Glucose infusion rate (GIR) (G) and arterial glucose levels (H) were measured during the euglycemic-hyperinsulinemic clamp on day 7 of
intracerebroventricular infusion in separate groups of rats. *P < 0.05 vs. vehicle (Veh).
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infused hFGF21 may protect against hepatic lipid accumu-
lation in the insulin-stimulated state, but not in settings
where insulin levels are not elevated.
Effect of central hFGF21 infusion on energy ho-
meostasis and glucose metabolism in lean rats. To
determine whether effects of central hFGF21 infusion on
energy homeostasis and insulin sensitivity are limited to
obese rats, either saline or hFGF21 (0.40 g/day) was
infused for 7 days into the lateral ventricle of lean,
chow-fed rats. Although no net changes in body weight
were observed over the 7-day infusion period (Fig. 5A),
daily food intake was increased on days 5 through 7 in
animals receiving intracerebroventricular hFGF21 relative
to vehicle (Fig. 5B), analogous to what was observed in
DIO rats (Fig. 1). After 5 days of continuous intracerebro-
ventricular infusion, insulin-induced glucose lowering was
unchanged in the hFGF21-infused rats relative to vehicle
during an ITT (data not shown). Because differences in
insulin tolerance can be difﬁcult to see in already insulin-
sensitive lean rats, we also subjected them to an intraperi-
toneal glucose tolerance test (IPGTT) and found that
glucose tolerance was increased in intracerebroventricu-
lar hFGF21-treated rats relative to vehicle (Fig. 5C). No
differences in plasma insulin (4 h after the IPGTT) or
glucose levels (4-h food-deprived or fasted) were observed
between intracerebroventricular hFGF21 vs. vehicle-in-
fused rats (data not shown). Hepatic glycogen content
tended to be higher in hFGF21-infused rats relative to
vehicle (93.9  4.1 vs. 72.4  10.8 ng/mg tissue for hFGF21
vs. vehicle), but this effect did not achieve statistical
signiﬁcance (P  0.06).
DISCUSSION
The wide-ranging effects of systemic hFGF21 administra-
tion on body composition, energy balance, substrate use,
and insulin sensitivity suggest a central site of action. This
hypothesis is strengthened by evidence that the hepatic
TABLE 1
Basal and clamp characteristics of DIO rats receiving continuous
intracerebroventricular infusion of either hFGF21 or vehicle
Vehicle hFGF21
n 67
Basal
Body weight (g) 527.1  18.9 561.1  26.7
 Body weight (g) 23.0  3.2 25.6  4.4
HFD intake (g/5 days) 62.6  4.2 84.6  4.8*
Plasma hFGF21 N.D. N.D.
Arterial plasma glucose
(mg/dl) 112.2  4.0 104.0  5.0
Plasma insulin (ng/ml) 2.40  0.68 2.12  0.54
Plasma nonesteriﬁed fatty
acids (mmol/l) 0.39  0.020 0.41  0.014
Plasma triglycerides
(mg/dl) 41.0  4.3 48.3  6.0
Clamp
Arterial plasma glucose
(mg/dl) 110.7  5.4 116.0  2.4
Plasma insulin (ng/ml) 6.6  0.35 7.1  0.90
GIR (mg/kg/min) 2.6  0.24 4.4  0.10*
Hepatic glycogen
(ng/mg tissue) 144.1  12.4 152.7  12.5
Data are means  SEM. N.D., not determined. *P  0.05 vs. vehicle.
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FIG. 3. Central infusion of hFGF21 improves insulin sensitivity by
increasing insulin-mediated suppression of endogenous glucose pro-
duction. Rate of endogenous glucose appearance (Endo Ra) during the
basal () and clamp (f) periods (A), percent suppression of hepatic
glucose production (B), rate of glucose disposal during the basal and
clamped periods (C), and percent increase in glucose utilization (D)
during euglycemic-hyperinsulinemic clamps performed during continu-
ous intracerebroventricular infusion of hFGF21 (0.40 g/day) or vehi-
cle as in Fig. 2. *P < 0.05 vs. vehicle (Veh).
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FIG. 4. Effect of central hFGF21 infusion on hepatic genes involved in
gluconeogenesis and lipid metabolism. Hepatic levels of mRNA encod-
ing gluconeogenic and lipid metabolic genes measured in either the
presence (e.g., after the clamp) (A) or absence of hyperinsulinemia
(e.g., after a 4-h fast) (B) in rats (n  6–7 per group) receiving
continuous intracerebroventricular infusion of hFGF21 (0.40 g/day)
or vehicle. *P < 0.05 vs. vehicle (Veh).
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mediated indirectly (6) and that FGF21 enters the brain
from the circulation (10). Here we report that chronic
central infusion of hFGF21 in rats with DIO increases
insulin sensitivity selectively in the liver and that this effect
is not due to reduced body fat mass.
Our ﬁnding that intracerebroventricular hFGF21 infu-
sion enhances insulin-mediated suppression of hepatic
glucose production, while having no effect on glucose
utilization, is reminiscent of the action of several other
hormone- and nutrient-related signals that regulate glu-
cose metabolism through a central mechanism. These
include insulin, leptin, FFAs such as oleate, and glucose
itself (11–17), each of which enhances hepatic insulin
sensitivity via an action involving the hypothalamus. More-
over, the effect of each of these interventions to increase
hepatic insulin sensitivity is accompanied (and potentially
mediated) by enhanced insulin-mediated suppression of
hepatic G6Pase and Pepck expression (11–14), as was
observed for intracerebroventricular hFGF21. Because
ﬁbroblast growth factor receptor (FGFR)-1, one of a
family of FGFRs that mediate FGF21 signal transduction,
is concentrated in hypothalamic areas such as the arcuate
and ventromedial nuclei of the hypothalamus that mediate
the metabolic effects of insulin, leptin, oleate, and glucose
(16–19), we hypothesize that neurocircuits involved in
the response to FGF21 overlap with those mediating the
action of key hormone- and nutrient-related stimuli, and
studies to test this hypothesis are a high priority.
Our understanding of how FGFRs mediate FGF21 signal
transduction is incomplete. Studies from cell culture mod-
els have demonstrated that FGFR1, FGFR2, and FGFR3
can mediate cellular responses to FGF21, including phos-
phorylation of the receptor, receptor substrate, and mito-
gen-activated protein kinase, leading to induction of Egr-1
gene expression, and have identiﬁed 	-klotho as an indis-
pensable FGF21 cofactor (20–22, 24). The recent ﬁnding
that FGF21 can induce signal transduction even in
	-klotho knockout mice (23), however, suggests that at
least in some tissues, 	-klotho may not be required for
FGF21-mediated signaling. Future studies are warranted
both to determine whether FGFR1 and 	-klotho are essen-
tial mediators of the effects of FGF21 in the CNS and to
identify the neuronal subsets involved. In addition, be-
cause several other FGF family members can signal
through the same FGFRs, it will be of interest to determine
whether they exert central effects that alter energy balance
or glucose metabolism.
One key difference between our ﬁndings and effects
reported during peripheral hFGF21 infusion is that sys-
temic, but not intracerebroventricular, FGF21 administra-
tion reduces body fat content. Interestingly, this effect is
mediated by increased energy expenditure with no change
of food intake (3). Although both central and systemic
hFGF21 treatment increases metabolic rate, we observed
a sustained increase of food intake during intracerebro-
ventricular hFGF21 infusion that prevented any overall
change in energy balance or body composition. Although
the mechanisms underlying this hyperphagia await further
study, we hypothesize that this response was elicited as a
result of increased metabolic rate. This hypothesis is
supported by the relatively late onset of hyperphagia,
which became evident only after 3 days of intracerebro-
ventricular infusion, along with the fact that during periph-
eral infusion, energy expenditure increases within the ﬁrst
24 h of FGF21 administration (our unpublished data and
ref. 4). However, we cannot at this time exclude the
possibility that the hyperphagia we observed is a direct
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FIG. 5. Effect of central hFGF21 infusion on energy homeostasis and glucose metabolism in lean rats. Percent body weight change (A), cumulative
food intake (days 5–7) (B), and results obtained during an IPGTT, including percent change from basal blood glucose levels (C) and area under
the curve (AUC) (D) in chow-fed adult male rats (n  4 per group) receiving continuous intracerebroventricular infusion of either hFGF21 (0.40
g/day) or vehicle for 7 days *P < 0.05 vs. vehicle (Veh).
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secondary response to increased energy expenditure, and
further studies are warranted to investigate this question.
Combined with our ﬁnding that unlike systemic treatment
(4), intracerebroventricular hFGF21 infusion did not in-
crease physical activity, these observations suggest that a
peripheral site of action is required for the capacity of
FGF21 to promote negative energy balance and weight
loss but not to increase either metabolic rate or liver
insulin sensitivity.
Although central hFGF21 infusion had no effects on
either hepatic fat content or respiratory quotient (a mea-
sure of total body fat oxidation), analysis of its effect on
hepatic expression of genes involved in lipid metabolism
suggest that it may nonetheless promote lipid oxidation
while decreasing lipid storage in the insulin-stimulated
state (an effect that is lost in the nonstimulated state).
Further, our ﬁnding that the effect of intracerebroventric-
ular hFGF21 on liver gene expression resembles that
reported during peripheral infusion of much larger FGF21
doses (3,4) suggests that peripheral FGF21 affects the liver
at least in part via an action in the CNS. Because FGF21
reduces liver fat content after peripheral but not central
administration, it is possible that in the latter setting,
improvements in hepatic lipid metabolism are offset by
increased caloric intake. Alternatively, peripheral actions
of FGF21 may promote the clearance of liver fat via
mechanisms additional to those involving the CNS. In
either case, amelioration of hepatic steatosis is not re-
quired for the insulin-sensitizing action of hFGF21 in the
brain. Lastly, we note that changes in hepatic expression
of genes involved in both gluconeogenesis and lipid me-
tabolism induced by intracerebroventricular hFGF21 were
sensitive to ambient insulin levels. Similarly, the effect of
centrally acting hFGF21 on insulin sensitivity was only
reliably detectable during the clamp conditions in which
plasma insulin levels are raised to values in the high
physiologic range. This outcome again is reminiscent of
what is seen with other hormones and nutrients that act in
the hypothalamus to increase peripheral insulin sensitivity
(3,4) and raise interesting possibilities for future study.
Although this study was undertaken primarily to deter-
mine whether central hFGF21 infusion mimics the beneﬁ-
cial effects observed during systemic administration in rats
with DIO, our ﬁndings suggest that the metabolic effects of
central FGF21 action are not limited to obese animals
consuming a HFD. Our preliminary results in lean, chow-
fed rats show that intracerebroventricular hFGF21 in-
creased food intake while having no net effect on body
weight, as was observed in rats rendered obese by high-fat
feeding. Although metabolic rate was not measured in lean
animals, this combination of ﬁndings is suggestive of
increased energy expenditure, as was observed in DIO
rats. Similarly, glucose tolerance was increased by intra-
cerebroventricular hFGF21 administration to lean, chow-
fed animals, although insulin sensitivity has yet to be
formally assessed in this setting, and additional studies are
warranted to more deﬁnitively investigate this response.
A substantial physiologic role for FGF21 in nutrient
metabolism is suggested by evidence that FGF21-deﬁcient
mice are prone to late-onset weight gain and exhibit
metabolic defects including decreases of ketogenesis, glu-
cose tolerance, and metabolic rate (1). In light of our
current work, the observation that circulating FGF21
levels increase during high-fat feeding in type 2 diabetes
and during both fasting and refeeding (25–27) raises the
question of whether physiologic responses induced by
changing FGF21 levels in these conditions involve a cen-
tral site of action. Similarly, our ﬁndings support the
possibility that a central mechanism mediates the effect of
peripherally administered hFGF21 to improve hepatic
insulin sensitivity (25–27), a testable hypothesis relevant
to ongoing and future efforts to investigate the utility of
FGF21 in the treatment of human obesity and diabetes.
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